ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJAKAL
1
Deal DateR&DLicensor CategoryClientStageUpfront Cash ($M)Deal Size ($M)Maximum Share (%)Deal TypesDeal SourceHas TagsDeal SubjectDeal LinkDiseaseIndicationTechnologySub-TechnologyExclusivityTerritoryUpfront Equity ($M)Contingent Equity ($M)R&D Support ($M)FTE Rate ($M)Loan ($M)Dev / Reg Milestones ($M)Other Milestones ($M)Total Precommercial Payments ($M)Sales Milestones ($M)Deal Size ($M)EFR$200M (%)EFR$500M (%)EFR$1B (%)Maximum Royalty (%)Marketing Fee (%)Transfer Price (%)Manufacture Cost + (%)Profit Split (%)Financial Term Explanations
2
3/2020Generex BiotechnologyBiotech
Sinotek-Advocates International, Beijing Zhonghua
Lead Molecule 5.00 6.00 20.00 Development, License, SupplySEC FullYesCOVID-19 vaccine dev via Ii-Key peptide vaccine platform in Greater ChinaLinkInfectious-ViralCoronavirusPeptides, VaccinesAsia 1.00 6.00 6.00 20.00 $1M initial dev cost pre-payment
3
3/2020Premas BiotechBiotech
Akers Biosciences, Cystron Biotech
Lead Molecule 0.25 2.00 LicenseSEC FullYesD-Crypt platform for COVID-19 vaccineLinkInfectious-ViralCoronavirusVaccinesExclusiveWorldwide 1.75 2.00 2.00 royalty-free
4
2/2020University of PittsburghResearch InstitutionGenprexPreclinical 0.21 4.19 3.00 LicenseSEC FullYesAAV gene therapy of Pdx1 and MafA genes for diabetesLinkEndocrinological & MetabolicDiabetesOligonucleotidesGene TherapyExclusiveWorldwide 3.98 4.19 4.19 3.00 3.00 3.00 3.00 $25K upfront plus $30K patent reimb plus $155K over 5 yrs
5
11/2019North Carolina State UniversityResearch InstitutionHoth TherapeuticsLead Molecule 0.03 0.61 2.50 License, ResearchSEC FullYesExon skipping for treating allergic diseases including asthmaLinkAllergic, RespiratoryAsthmaOligonucleotides
Antisense/Triple helix, Gene Therapy
ExclusiveWorldwide 0.59 0.61 0.61 2.50 2.50 2.40 2.50
6
4/2019PulmatrixBiotechCipla, Cipla TechnologiesPhase II 22.00 22.00 50.00 Co-Development, Letter of Intent, LicenseSEC FullYesPulmazole (inhaled iSPERSE formulation of itraconazole) for allergic bronchopulmonary aspergillosisLinkInfectious-Miscellaneous, RespiratoryBroad Focus Respiratory, Asthma, FungalDrug Delivery, SyntheticsOther, Small MoleculeExclusiveWorldwide 22.00 50.00 50/50 sharing of dev costs after initial $24M spent by Pulmatrix
7
2/2019MedtronicMid Tier PharmaUnited TherapeuticsDevice 10.00 License, SupplySEC FullYesDelivery of Remodulin (treprostinil) via implantable pumps & catheters for PAH in USLinkCardiovascularHypertensionDeviceExclusiveNAFTA 10.00 10.00 10.00 10.00 10% royalty on Drug sales using the Medronic delivery systems
8
2/2019NLS PharmaceuticsBiotechEurofarma LaboratoriosPreclinical 2.50 18.50 10.00 Co-Development, License, SupplySEC FullYesNolazol (Mazindol CR) for ADHD in S AmericaLinkPsychiatricAttention Deficit Hyperactivity DisorderDrug DeliveryControlled ReleaseExclusive
NAFTA, South America
3.00 5.50 13.00 18.50 9.70 9.90 10.00 10.00
9
10/2018NeuRx PharmaceuticalsBiotechNeos TherapeuticsPreclinical 0.18 5.63 11.00 LicenseSEC FullYesOral NT0501 (NRX 101 mascarinic rec antag) for sialorrhea (drooling)LinkCentral Nervous SystemOther Central Nervous SystemDrug Delivery, Synthetics
Microspheres, Oral, Small Molecule
ExclusiveWorldwide 2.95 2.50 5.63 5.63 8.00 9.60 10.30 11.00
10
7/2018ABL BioBiotechI-MabLead Molecule 50.00 Co-Development, License, OptionSEC FullYesThree bispecific antibodies (PD-L1 with TIGIT, 4-1BB or B7H3) for immuno-oncologyLinkCancerBroad Focus CancerMonoclonalsBispecificExclusiveWorldwide 50.00
equal sharing of dev costs | 50% PS assuming both opt-in for 4-1BB or B7H3
11
6/2018Jaguar Health, Napo PharmaceuticalsBiotechRedHill BiopharmaApprovedCo-PromotionFOIAYesMytesi crofelemer CR tablets for diarrhea in HIV patients to GI specialists in USLinkGastrointestinal, Infectious-Viral
Bowel Movement Disorders, Human Immunodeficiency Virus/HIV
Drug DeliveryControlled ReleaseSemi-exclusiveNAFTA
12
6/2018University of LouisvilleResearch InstitutionRitter Pharmaceuticals, QualigenDiagnostic 0.35 7.00 5.00 LicenseSEC FullYesAnti-nucleolin agent-conjugated nanoparticles as MRI contrast agentsLinkCancerDiagnosis - Contrast/ImagingDiagnostics, Drug DeliveryMicrospheresExclusiveWorldwide 1.15 0.50 2.00 5.00 7.00 4.00 4.50 4.75 5.00 $50K upfront, $250K for patent exp. plus $50K maintenance fees
13
4/2018Brigham and Women’s HospitalResearch InstitutionTiziana Life SciencesPreclinical 0.04 5.44 1.50 LicenseSEC FullYesForalumab nasal formulation for NASH & Crohn'sLinkAutoimmune/Inflammatory, Gastrointestinal
IBD - Crohn's Disease, Other Autoimmune/Inflammatory
Drug DeliveryNasalExclusiveWorldwide 5.40 5.44 5.44 1.50 1.50 1.50 1.50 $10K plus $5K AMF
14
4/2018Horizon DiscoveryBiotechCelyadDiscovery 0.10 15.10 2.00 License, Option, ResearchSEC FullYesshRNA technology to generate allogeneic CAR-T therapies for cancerLinkCancerCell Therapy - Stem Cells/FactorsExclusiveWorldwide 7.75 7.25 15.10 15.10 2.00 2.00 2.00 2.00
15
3/2018Ionis PharmaceuticalsBiotechAkcea TherapeuticsFiled 1,680.00 50.00
Co-Development, Co-Promotion, Equity, License
SEC FullYesInotersen and IONIS-TTR-L Rx for hereditary transthyretin amyloidosisLinkOther/MiscellaneousGenetic DisordersOligonucleotidesGene TherapyExclusiveWorldwide 150.00 110.00 145.00 405.00 1,275.00 1,680.00 50.00
$150M of FMV of Akcea's shares as upfront payment to Ionis; Ionis also purchased $200M of Akcea's common shares at same price, per Akcea's 3/15/18 8-K (see Equity agmt) | Initially 60% PS to Ionis for Inotersen, then 50/50 for both Products,
16
2/2018Actigen, PharmstandardBiotechArgos TherapeuticsLead Molecule 12.10 7.00 Equity, License, OptionFOIAYesPD-1 antibody in NALinkCancerBroad Focus CancerMonoclonalsExclusiveNAFTA 0.36 3.24 8.50 12.10 12.10 7.00 7.00 7.00 7.00
$360K in Argos shares as option fee | $3.24M of Argos equity on exercise of license option
17
1/2018Aeterna ZentarisBiotechStrongbridge BiopharmaApproved 24.00 203.00 18.00 Co-Development, LicenseSEC FullYesMacrilen (macimorelin) for growth hormone deficiency in NALinkEndocrinological & MetabolicGrowth Hormone DisordersSyntheticsSmall MoleculeExclusiveNAFTA 5.00 29.00 174.00 203.00 16.88 17.55 17.78 18.00
Strongbridge will fund 70% of the costs of a worldwide pediatric development program to be run by AZ
18
1/2018I-MabBiotechEverest MedicinesPhase I 45.00 Co-Development, LicenseSEC FullYesTJ202 (MOR202 anti-CD38 Mab) for multiple myeloma in Greater ChinaLinkCancerMultiple MyelomaMonoclonalsSemi-exclusiveAsia 45.00 Everest pays 75% of dev cost | 45% PS to I-Mab
19
12/2017GenexineBiotechI-MabPhase I 12.00 560.00 3.00 LicenseSEC FullYesTJ107 HyLeukin (long-acting IL-7 fusion protein) for immuno-oncology in Greater ChinaLinkCancerBroad Focus CancerDrug Delivery, Recombinant DNAOtherExclusiveAsia 23.00 35.00 525.00 560.00 3.00 3.00 3.00 3.00
20
11/2017
Generex Biotechnology, NuGenerex Immuno-Oncology
Biotech
Shenzhen BioScien Pharmaceuticals
Phase I 0.70 4.70 10.00 License, ResearchSEC FullYesAE37 immunotherapeutic vaccine for prostate cancer in ChinaLinkCancerProstatePeptides, VaccinesExclusiveAsia 4.00 4.70 4.70 10.00 10.00 10.00 10.00
21
7/2017CellectisBiotechCalyxtOther 20.00 3.00 Equity, LicenseSEC FullYesTalen gene editing technology for agriculture and feed ingredientsLinkOther/MiscellaneousAgricultureOligonucleotidesGene TherapyExclusiveWorldwide 20.00 20.00 20.00 3.00 3.00 3.00 3.00 Celectis purchased $20M of Calyxt's IPO in 7/17
22
7/2017Immune Pharmaceuticals, Cytovia IncBiotechPint PharmaPhase III 5.75 35.00 Distribution, Equity, LicenseSEC FullYesCeplene (histamine dihydrochloride) for acute myeloid leukemia in Mexico & S. AmericaLinkCancerLeukemiaSyntheticsSmall MoleculeExclusive
NAFTA, South America
4.00 1.75 5.75 35.00 $4M cash for Cytovia eq
23
1/2017Forward PharmaBiotechBiogenApproved 1,250.00 1,250.00 20.00 License, SettlementSEC FullYesIP related to dimethyl fumarate for multiple sclerosisLinkCentral Nervous SystemMultiple SclerosisSyntheticsSmall MoleculeExclusiveWorldwide 1,250.00 1,250.00 10.00 10.00 10.00 20.00
10% royalty until 12/31/28 and 20% thereafter until patent expiration
24
12/2016Novimmune SABiotechTiziana Life SciencesPreclinical 0.10 0.10 2.00 LicenseSEC FullYesNI-1201 fully human anti-IL-6R mAb for autoimmune and inflammatory diseasesLinkAutoimmune/InflammatoryBroad Focus Autoimmune/InflammatoryMonoclonalsHuman AbsExclusiveWorldwide 0.10 0.10 2.00 2.00 2.00 2.00
25
11/2016Ferring PharmaceuticalsMid Tier PharmaI-MabPhase I 2.00 49.50 LicenseSEC FullYesTJ301 olamkicept (FE-301 IL-6 inhibitor) for ulcerative colitis in Greater China and S KoreaLinkGastrointestinalIBD - Ulcerative ColitisExclusiveAsia 14.50 33.00 49.50 49.50 7.00 7.60 7.80 10.00
6-8% in Territory; 8-10% in Expanded Territory if option exercised | $3M option payment plus $30M dev/reg milestones if territory expanded to NA, EU & Japan
26
11/2016University of IllinoisResearch InstitutionG1 TherapeuticsLead Molecule 0.73 3.35 3.00 LicenseFOIAYesG1T48 (oral selective estrogen receptor degrader SERD) for breast cancerLinkCancerBreastSyntheticsSmall MoleculeExclusiveWorldwide 2.63 3.35 3.35 3.00 3.00 3.00 3.00 $500K upfront plus $225K in maintenance fees
27
10/2016Dare Bioscience, Cerulean PharmaBiotechNovartisDiscovery 5.00 242.00 10.00 Development, License, OptionFOIAYesNanoparticle-drug conjugates against FGFR and four add'l cancer targetsLinkCancerBroad Focus CancerSyntheticsPolymersExclusiveWorldwide 3.50 0.35 48.50 57.00 185.00 242.00 3.00 3.00 4.00 10.00 $185M per Program | 5 FTEs/yr for 2 yrs | $48.5M per Program
28
10/2016TheravectysBiotechImmune DesignDiscovery 7.25 25.75 1.25 License, SettlementFOIAYesLentiviral vector technology for cancer vaccineLinkCancerBroad Focus CancerVaccinesNon-exclusiveWorldwide 4.00 2.00 13.25 12.50 25.75 1.25 1.25 1.25 1.25
$6M upfront plus add'l $1.25M on IMDZ IPO (see Settlement agmt) | $2M for 2nd product approval
29
10/2016University of MiamiResearch InstitutionHeat BiologicsLead Molecule 0.03 1.48 5.00 LicenseFOIAYesGP96-Ig-based vaccine for immunity against Zika VirusLinkInfectious-ViralOther Infectious-ViralVaccinesExclusiveWorldwide 1.45 1.48 1.48 5.00 5.00 5.00 5.00 $20K upfront plus $8K in MF
30
9/2016
Cancer Research Technology, Cancer Research UK, CRT Pioneer
Research InstitutionSierra OncologyPhase I 7.00 328.50 10.00 LicenseFOIAYesSRA737 (checkpoint kinase Chk1 inhibitor) for cancerLinkCancerBroad Focus CancerSyntheticsSmall MoleculeExclusiveWorldwide 91.50 50.00 148.50 180.00 328.50
31
9/2016GlaxoSmithKline, TesaroBiotechZai LaboratoryPhase III 15.00 54.50 18.00 Co-Promotion, License, OptionFOIAYesNiraparib (PARP inhibitor) for ovarian cancer in China, Hong Kong & MacauLinkCancerBroad Focus Cancer, OvarianSyntheticsSmall MoleculeExclusiveAsia 3.50 18.50 36.00 54.50 15.00 16.80 17.40 18.00 5.00 50.00
Tesaro to supply at 105% Manu Cost if requested by Zai | 50% PS in China in lieu of milestones/royalties in event Tesaro elects to co-promote
32
7/2016TiGenixBiotechTakedaFiled 27.70 432.60 20.00 Distribution, Equity, LicenseSEC FullYesCx601 (eASC stem cells) to treat perianal fistulas in patients with Crohn’s disease ex-USLinkGastrointestinal
IBD - Crohn's Disease, Other Gastrointestinal
Cell Therapy - Stem Cells/FactorsExclusive
Africa, Asia, Europe, Middle East, NAFTA, South America
11.10 33.30 72.10 360.80 432.60 20.00
€25 million (US$27.7M) | €325 million (US$360.8M) | €10 million (US$11.1M) within 12 months | 10-20% royalties, depending on product price and sales level | €18 million for regulatory approvals, plus €12 million for pricing reimbursement approvals
33
6/2016Cell Design LabsBiotechGilead, Kite PharmaDiscovery 2.00 64.50 7.00
Development, Equity, License, Option, Research
FOIAYesMolecular on/off switch for CAR T-cell immunotherapies forAML & B-cell malignanciesLinkCancerLeukemia, LymphomaCell Therapy - Stem Cells/FactorsExclusiveWorldwide 7.00 11.00 0.31 27.00 17.50 64.50 64.50 4.00 4.00 5.50 7.00
$1M per-signing; $4M of Ser C @ $4.70/sh plus $2M of Ser B @ $3.75/sh | $8M max (8 FTEs/yr for 3 yrs @ $165/hour); Add'l $3M if Kite extends research term by 18 months | $165/hour
34
6/2016Gene Biotherapeutics, AngioneticsBiotechHuapont Life SciencesPhase III 3.00 10.00 Distribution, EquitySEC FullYesGenerx (Ad5FGF-4) for cardio in mainland ChinaLinkCardiovascularAngina, Myocardial InfarctionOligonucleotidesGene TherapyExclusiveAsia 1.00 2.00 3.00 3.00 5.75 7.30 8.65 10.00 20.00
$2M add'l share puchase on US Ph III commencement for ischemic heart disease and refractory angina, per Taxus' 6Q16
35
6/2016Kyowa Hakko KirinMid Tier PharmaCerecor, Aevi Genomic MedicinePhase I 2.00 20.00 50.00 Co-Development, License, Option, SupplyFOIAYesAnti-LIGHT (TNFSF14 mAb) for severe pediatric onset IBD in NALinkGastrointestinalIBD - OtherMonoclonalsHuman AbsExclusiveNAFTA 0.35 18.00 20.00 20.00 13.00 10.00 50.00
$2M on license exercise | equal sharing up to $17.5M aggergate, then all by Medgenics in Territory & EU | $150K-$350K/FTE | KHK pays 13% royalty to Medgenics on EU sales | 50/50 PS in NA if KHK co-develops; otherwise 74% PS to Medgenics
36
6/2016Sesen BioBiotechRochePreclinical 7.50 270.00 License, OptionSEC FullYesEBI-031 (IL-6 antagonist antibody) for diabetic macular edema and uveitisLinkOphthalmicBroad Focus OphthalmicMonoclonalsHumanized AbsExclusiveWorldwide 197.50 65.00 270.00 270.00 7.50 7.50 7.50 15.00
37
5/2016Carna BiosciencesBiotechSierra OncologyPreclinical 0.90 270.90 7.00 LicenseFOIAYesSRA141 (Cdc7 kinase inhibitor) for cancerLinkCancerBroad Focus CancerSyntheticsSmall MoleculeExclusiveWorldwide 57.00 23.00 80.90 190.00 270.90 4.00 4.00 4.50 7.00
38
5/2016
Fortress Biotech, Checkpoint Therapeutics
BiotechTG TherapeuticsPreclinical 1.00 177.90 5.00 Co-Development, LicenseFOIAYesJBET070 & JBET050 (BET inhibitors) for hematological malignanciesLinkCancerLeukemia, Lymphoma, Multiple MyelomaSyntheticsSmall MoleculeExclusiveWorldwide 51.25 36.40 88.65 89.25 177.90 5.00 5.00 5.00 5.00
$52.5M for 1st & $36.75M for 2nd Product | 50/50 cost sharing thru pre-clinical then all by TG
39
5/2016Immune PharmaceuticalsBiotechNovel Pain TherapeuticsPhase II 161.00 10.00 Development, Equity, License, OptionSEC FullYesAmiKet and AmiKet Nano for peripheral neuropathic painLinkCentral Nervous SystemPainDrug Delivery, SyntheticsSmall Molecule, TopicalExclusiveWorldwide 15.00 1.00 25.00 41.00 120.00 161.00 7.50 8.75 9.38 10.00 $1-10M in R&D funding, depending on dev plan
40
4/2016AmyrisBiotechBill & Melinda Gates FoundationDiscovery 0.01 5.01 Equity, LicenseSEC FullYesEquity investment to fund malaria treatment programLinkNon-exclusiveWorldwide 5.00 5.01 5.01
41
4/2016Aratana TherapeuticsBiotechLilly, ElancoApproved 45.00 149.00 18.75
Co-Development, Co-Promotion, License, Supply
FOIAYesGalliprant (grapiprant tablets) for osteo pain in dogsLinkOther/MiscellaneousVeterinaryExclusiveWorldwide 21.00 8.00 74.00 75.00 149.00 10.00 10.00 10.00 18.75
Aratana pays 25% of dev costs, up to $7M max | 13.75% US royalty (25% GM, where GM = 55% of US sales) plus 5% add'l US royalty thru 12/31/18; 10% ex-US royalty (see Co-Promotion agmt)
42
4/2016GlaxoSmithKline, TesaroBiotechJohnson & Johnson, JanssenPhase III 35.00 500.00 5.00 Equity, LicenseFOIAYesNiraparib (PARP inhibitor) for prostate cancer ex-JapanLinkCancerProstateSyntheticsSmall MoleculeExclusive
Africa, Asia, Europe, Middle East, NAFTA, South America
50.00 0.30 90.00 75.00 250.00 250.00 500.00 3.00 3.30 4.30 5.00 5.00
$50M equity investment, at a price of $44.24/sh | 3-5% to Tesaro; Janssen pays 10-14% pass-through royalty to Merk, plus 1-4% add'l to 3rd parties | $90M for metastatic castration-resistant prostate cancer
43
4/2016Juno TherapeuticsBiotechCelgenePhase II 50.00 50.00 14.00
Co-Development, Co-Promotion, License, Option
FOIAYesJCAR-015 & CD19 program for acute lymphoblastic leukemia ex-NA & ChinaLinkCancerLeukemiaCell Therapy - Stem Cells/FactorsExclusive
Africa, Asia, Europe, Middle East, NAFTA, South America
50.00 50.00 14.00 14.00 14.00 14.00 14% royalty
44
4/2016Progenics PharmaceuticalsBiotechBayerLead Molecule 4.00 183.00 LicenseFOIAYesPSMA antibody Conjugated with targeted thorium for prostate cancerLinkCancerProstateMonoclonals
Conjugates, Human Abs
ExclusiveWorldwide 49.00 53.00 130.00 183.00 3.00 3.00 3.50 5.00
45
4/2016TakedaTop Pharma
Roivant Sciences, Myovant Sciences
Phase II 8.00 Equity, License, Supply, WarrantFOIAYesRelugolix (RVT-602 GnRH ra) for menstrual bleeding, & prostate cancer ex-Japan, China, Korea & AseanLinkCancer, Genitourinary/Gynecologic
Infertility, Prostate, Other Genitourinary/Gynecologic
Peptides, SyntheticsSmall MoleculeExclusive
Africa, Asia, Europe, Middle East, NAFTA, South America
0.30 8.00 8.00 8.00 8.00
9M common shares (12% of OS), converted to 5.1M shares per Myovant's IPO prospectus | warrant at no add'l cost to provide full-ratchet anti-dilution through 1st anniv of signing at 12% OS; (154K and 82K add'l shares issued to Takeda in 6/16 & 8/16, plus 2M at IPO, per Myovant's IPO prospectus) | 8% to Takeda in Myovant Territory (and same royalty to Myovant in Takeda Territory)
46
3/2016Arcturus TherapeuticsBiotechProvidence TherapeuticsDiscovery 0.50 0.50 25.00
Co-Development, Joint Venture, License, Research
SEC FullYesIndividualized LUNAR delivery of mRNA vaccine for brain, breast and ovarian neoplasmsLinkCancerBrain, Breast, OvarianDrug Delivery, VaccinesOtherExclusiveWorldwide 0.35 0.50 0.50 25.00 25% PS to Arcturus (unless opt-out)
47
1/2016
Hebrew University, Yissum Research Development
Research InstitutionImmune PharmaceuticalsPreclinical 0.53 5.33 5.00 Development, Equity, License, ResearchSEC FullYesTopical delivery of Cyclosporine A by means of biodegradable
nanoparticles
LinkDrug Delivery, SyntheticsSmall Molecule, TopicalExclusiveWorldwide 0.30 3.50 1.00 5.33 5.33 5.00 5.00 5.00 5.00
48
1/2016Ludwig Cancer ResearchResearch InstitutionAgenus, 4-AntibodyLead Molecule 44.00 1.00 License, RestatementFOIAYesHuman antibodies to CTLA-4 and PD-1LinkCancerBroad Focus CancerMonoclonalsHuman AbsExclusiveWorldwide 44.00
49
1/2016MacrolideBiotechMelinta Therapeutics, CempraLead Molecule 0.75 5.25 0.75 License, Option, Research, TerminationFOIAYesMethods of synthesizing solithromycin ex-AseanLinkInfectious-BacterialBroad Focus Infectious-BacterialExclusive
Africa, Asia, Europe, Middle East, NAFTA, South America
1.50 2.00 4.25 1.00 5.25 0.50 0.50 0.60 0.75 $1.5M over 18 months
50
12/2015Ionis PharmaceuticalsBiotechAkcea TherapeuticsPhase III 150.00 25.00
Development, Equity, License, Loan, Services
SEC FullYesSpinout of volanesorsen, APO(a)-LRx, ANGPTL3-LRx and APOCIII-LRx lipid drugsLinkOther/MiscellaneousGenetic DisordersOligonucleotidesAntisense/Triple helixExclusiveWorldwide 150.00 150.00 150.00 25.00 25.00 25.00 25.00
25% royalty on volanesorsen, 15-20% on other Products,, depending on disease population | $150M credit facility from Ionis to Akcea (see seaparate agmt)
51
9/2015NIHResearch InstitutionGilead, Kite PharmaPhase I 1.64 22.17 4.25 LicenseFOIAYesIP covering T cell receptor-based products targeting MAGE A3 and A3/A6 antigensLinkCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsExclusiveWorldwide 5.65 2.88 10.17 12.00 22.17 4.25 4.25 4.25 4.25
$1.2M plus $75K AMF plus $136K patent reimb | $2.875M for 2nd indication
52
8/2015AdvaxisBiotechKnight TherapeuticsPhase II 36.50 20.00 Equity, License, SupplyFOIAYesAxalimogene filolisbac (ADXS-HPV), ADXS-PSA and ADXS-HER2 in CanadaLinkCancerCervical, ProstateVaccinesExclusiveNAFTA 5.00 20.00 25.00 11.50 36.50 20.00
$20M in Advaxis equity by Knight investment group, per Advaxis' 2016 10-K
53
8/2015
AVEO Pharmaceuticals, Aveo Oncology
BiotechNovartisPreclinical 18.45 326.45 12.00 License, TerminationFOIAYesAV-380 (anti-GDF15 antibody) for cachexiaLinkCardiovascular, Renal, Respiratory
Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Other Renal
MonoclonalsHumanized AbsExclusiveWorldwide 108.00 50.00 176.45 150.00 326.45 7.00 7.00 8.00 12.00 $15M upfront, plus $3.45M for reimb of Ab
54
8/2015
AVEO Pharmaceuticals, Aveo Oncology
BiotechPharmstandardPhase III 1.50 12.00 7.00 License, TerminationFOIAYesTivozanib VEGF tyrosine kinase inhibitor excluding ocular conditions in Russia & CISLinkCancerBroad Focus CancerSyntheticsSmall MoleculeExclusiveEurope 0.35 7.50 3.00 12.00 12.00 7.00 7.00 7.00 7.00
55
8/2015Ember TherapeuticsBiotechKnight TherapeuticsPhase II 6.00 28.00 Distribution, Equity, License, LoanFOIAYesBone Morphogenetic Protein-7 for osteoarthritis & kidney disease in Canada, Russia, Israel & AfricaLinkAutoimmune/InflammatoryOsteoarthritisRecombinant DNAExclusive
Africa, Europe, Middle East, NAFTA
5.00 1.00 6.00 6.00 28.00 10.00
$5M in contingent equity, per 8/6/15 PR | greater of 28% of sales or Manu Cost plus 10%
56
8/2015Harrow HealthBiotechAdvanced Dosage FormsApproved 0.01 0.01 20.00 License, OptionSEC FullYesTri-Moxi, Pred-Moxi & Dex-Moxi for post-cataract eye care in CanadaLinkOphthalmicCataractsDrug DeliveryOtherNon-exclusiveNAFTA 0.01 20.00 20.00 20.00 20.00
57
7/2015LonzaBiotechCytoDynDiscovery 2.00 LicenseSEC FullYesGlutamine synthetase expression of PRO 140 monoclonal for HIVLinkInfectious-ViralHuman Immunodeficiency Virus/HIVMonoclonalsNon-exclusiveWorldwide 2.00 2.00 2.00 2.00
58
6/2015BioLytical LaboratoriesBiotechNetwork OncologyDiagnostic 0.25 0.25 9.00 Equity, License, SupplySEC FullYesEbola polypeptide as point of care diagnosticLinkInfectious-ViralCoronavirus, Other Infectious-ViralDiagnosticsImmunoassayNon-exclusiveWorldwide 0.25 0.25 9.00 9.00 9.00 9.00 15M shares of NOL | greater of 9% royalty or $0.50/unit
59
6/2015bluebird bioBiotechBristol-Myers Squibb, CelgeneLead Molecule 75.00 450.00 50.00
Co-Development, Co-Promotion, Equity, Option, Restatement
FOIAYesbb2121 (CAR-T cell therapy to BCMA target antigen) for oncologyLinkCancerBroad Focus Cancer
Cell Therapy - Stem Cells/Factors, Oligonucleotides
Gene TherapyExclusiveWorldwide 20.00 25.00 100.00 165.00 65.00 450.00 450.00 13.00 50.00
$165M for 1st, per 3/13 agmt | $75M, per 3/13 agmt | $20M at IPO, per 3/13 agmt | 6-13% royalty, per 3/13 agmt | $100M co-dev loan, per 3/13 agmt | $65M for 2nd product, per 3/13 agmt | 50% PS in US if co-dev, per 3/13 agmt
60
6/2015Elite PharmaceuticalsBiotechEpic PharmaPhase III 5.00 15.00 45.00 Co-Development, License, SupplyFOIAYesELI-200 (Oxycodone IR) abuse-deterrent opioid for pain in USLinkCentral Nervous SystemPainDrug DeliveryOtherExclusiveNAFTA 10.00 15.00 15.00 45.00 45.00 45.00 45.00 10.00 50% of Net Sales, less 5% as Marketing Fee
61
6/2015
Hebrew University, Yissum Research Development
Research InstitutionImmune PharmaceuticalsPreclinical 0.03 4.93 3.00 License, ResearchSEC FullYesTopical nano-formulation of AmiKet for painLinkCentral Nervous SystemPainDrug Delivery, SyntheticsSmall Molecule, TopicalExclusiveWorldwide 0.40 4.50 4.93 4.93 3.00 3.00 3.00 3.00
62
6/2015Juno TherapeuticsBiotechCelgenePhase II 150.20 1,150.20 50.00
Co-Development, Co-Promotion, Equity, License, Option
FOIAYesCAR-T and TCR technologies for cancer and autoimmune diseasesLinkAutoimmune/Inflammatory, Cancer
Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer
Cell Therapy - Stem Cells/FactorsExclusiveWorldwide 850.00 150.00 1,100.00 1,150.20 14.00 14.00 14.00 14.00 50.00
9.1M shares @ $93/sh | Celgene has contingent rights to purchase up to 30% OS of Juno, per Celgene corp presentation | 50% PS on Juno originated programs (other than CD19 or CD22) & 30% PS globally on Celgene-originated programs | $50-75M on option exercise for each of CD19 & CD22 Program, depending on stage at exercise | 14% ROW royalty for CD19 & CD22; 8-`14% for Undesignated IMM Programs, depending on stage at license -- see Exhibit C to 4/16 License amgt
63
6/2015PrecigenBiotechOragenicsPhase II 37.00 12.00 Equity, LicenseFOIAYesAG013 (oral rinse of Trefoil Factor 1) for chemo-induced mucositisLinkDental/OralMucositisPeptidesExclusiveWorldwide 5.00 22.00 10.00 37.00 37.00 12.00 12.00 12.00 12.00
dev milestones may be paid in cash or Oragenics shares | $22M in cash or equity
64
6/2015University of MinnesotaResearch InstitutionOxis International, Oxis BiotechPreclinical 0.35 9.50 4.00 LicenseSEC FullYesDT2219ARL bispecific scFv recombinant fusion protein-drug conjugate for B-cell malignanciesLinkCancerLeukemia, LymphomaMonoclonals, Recombinant DNABispecific, ConjugatesExclusiveWorldwide 2.90 0.25 3.50 6.00 9.50 4.00 4.00 4.00 4.00
$200K upfront plus $150K maintenance fees over 5 yrs | $250K for non-human use
65
5/2015Achillion PharmaceuticalsBiotechJohnson & Johnson, JanssenPhase II 1,130.00 22.00 Development, Equity, License, TerminationFOIAYesACH-3102 (NS5A inhibitor), ACH-3422 (NS5B) and sovaprevir (NS3/4A) for HCVLinkInfectious-ViralHepatitis CSyntheticsSmall MoleculeExclusiveWorldwide 225.00 0.30 405.00 630.00 500.00 1,130.00 15.00 15.00 15.00 22.00 18.4M shares @ $12.25/sh
66
5/2015BerylliumBiotechArQuleDiscovery 50.00
Co-Development, License, Research, Termination
FOIAYesScreening small molecules targeting PD-1 and PDL-1LinkCancerBroad Focus CancerScreening, SyntheticsSmall MoleculeExclusiveWorldwide 0.33 50.00
67
4/2015Celgene, Juno TherapeuticsBiotech
University of Pennsylvania, Novartis
Lead Molecule 12.25 138.00 4.75 License, SettlementFOIAYesSettlement of IP litigation related to CART-19 products (US 8,399,645)LinkCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsNon-exclusiveNAFTA 64.25 50.00 126.50 11.50 138.00 4.75 4.75 4.75 4.75 $64.25M for first non-orphan approval
68
4/2015Clearside BiomedicalBiotechSpark TherapeuticsPreclinical 0.50 29.00 7.50
Co-Development, License, Option, Research, Supply, Termination
FOIAYesMicroinjector technology to deliver gene therapies to the retina for macular edemaLinkOphthalmicUveitis, Other OphthalmicDrug Delivery, OligonucleotidesGene Therapy, OtherExclusiveWorldwide 16.50 17.00 12.00 29.00 4.50 4.50 4.50 7.50
4.5% for 1st Product; 5.5% for others; add'l 2% if only Clearside IP covering Product
69
3/2015EyenoviaBiotechSenju PharmaceuticalFormulation 5.00 5.00 Equity, LicenseSEC FullYesPiezoelectric delivery of ophthalmic medications in AsiaLinkOphthalmicBroad Focus OphthalmicDrug DeliveryOtherExclusiveAsia 5.00 5.00 5.00 5.00 5.00 5.00 5.00
$5M of Pref A shares of Eyenovia | 5% of Net Price (Net Sales less Manu Cost)
70
3/2015
Fortress Biotech, Checkpoint Therapeutics
BiotechTG TherapeuticsPreclinical 0.60 103.60 9.50 LicenseFOIAYesAnti-PD-L1 and anti-GITR antibodies for hematological malignanciesLinkCancerLeukemia, Lymphoma, Multiple MyelomaMonoclonalsHuman AbsExclusiveWorldwide 21.50 21.50 43.60 60.00 103.60 8.00 8.00 8.75 9.50
71
3/2015OrganovoBiotechLOrealOther 2.13 7.00 License, Option, Research, SupplyFOIAYesBioprinting on skin & other external tissues for cosmetic, oral & nutritional uses ex-USLink
Dental/Oral, Dermatologic, Other/Miscellaneous
Cosmetics, Nutritionals/Vitamins, Other Dental/Oral, Other Dermatologic
Cell Therapy - Stem Cells/FactorsExclusive
Africa, Asia, Europe, Middle East, NAFTA, South America
0.78 1.35 2.13 2.13 7.00 7.00 7.00 7.00
5-7% royalty, depending on Epidermal, Dermal or Full Thickness Skin Model | Supply terms TBD on MFL basis
72
3/2015Oxis International, Oxis BiotechBiotechMultiCell ImmunotherapeuticsPreclinical 0.50 15.88 3.00 License, Option, ResearchSEC FullYesThree antibody-drug conjugate products containing OXS-2175 and OXS-4235 for cancerLinkCancerBreast, Multiple MyelomaMonoclonals, Synthetics
Conjugates, Small Molecule
ExclusiveWorldwide 1.13 4.25 10.00 15.88 15.88 3.00 3.00 3.00 3.00
$10M if exercise manu option | $1.125M in R&D funding (see Res agmt)
73
3/2015vTv TherapeuticsBiotechCalithera BiosciencesPreclinical 0.60 109.20 7.00 License, Research, TerminationFOIAYesHPP399 (hexokinase II inhibitor) for cancerLinkCancerBroad Focus CancerSyntheticsSmall MoleculeExclusiveWorldwide 1.10 0.28 43.50 9.00 54.20 55.00 109.20 4.00 4.00 4.40 7.00 4 FTEs for 1 yr
74
3/2015Ziopharm, PrecigenBiotechMerck KGaA, Merck SeronoDiscovery 115.00 608.00 13.00
Assignment, License, Option, Research, Supply
FOIAYesChimeric antigen receptor T-cell (CAR-T) products for cancerLinkCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsExclusiveWorldwide 10.00 77.50 200.50 403.00 205.00 608.00 2.00 3.00 4.50 13.00
$205M per Product | $10M for first two Targets, plus $5M for each add'l Target selected by Serono | $77.5M for 1st indication | $130.5M for add'l indications, plus $20M if Serono opts-in for Out-of-Scope Target; $40M for Allogeneic Cell Therapy entering Ph II or III using cells not from patients in trial; $10M on initiation of Ph III for solid tumor indication
75
2/2015Canon U.S. Life SciencesBiotechT2 BiosystemsDiagnostic 2.00 8.50 20.00 Co-Development, LicenseFOIAYesT2MR (magnetic imaging) technology to diagnose Lyme diseaseLinkInfectious-BacterialLyme DiseaseDiagnosticsSemi-exclusiveWorldwide 6.50 8.50 8.50 20.00
T2 pays Canon 20% royalty until $6.5M, then 10% until $19.5M, then 2% thereafter
76
2/2015Janssen, Johnson & Johnson, ActelionBiotech
Allergan, Kythera Biopharmaceuticals
Phase II 1.50 27.05 9.00 LicenseFOIAYesSetipiprant (KYTH-105 prostaglandin D2 receptor antagonist to CRTH2) for hair lossLinkOther/MiscellaneousHair GrowthSyntheticsSmall MoleculeExclusiveWorldwide 20.75 4.80 27.05 27.05 6.75 8.10 8.55 9.00 6-9% for oral; 5-7% for topical
77
2/2015University of PennsylvaniaResearch Institution
Allergan, Kythera Biopharmaceuticals
Preclinical 0.22 4.34 3.50 LicenseFOIAYesIP covering use of PGD2 receptor antagonists for hair lossLinkOther/MiscellaneousHair GrowthSyntheticsSmall MoleculeExclusiveWorldwide 0.88 0.25 1.34 3.00 4.34 1.50 1.75 2.13 3.50
78
2/2015Voyager TherapeuticsBiotechSanofi, GenzymePhase I 65.00 810.00 15.00
Co-Development, Co-Promotion, Equity, License, Option, Supply, Termination
FOIAYesVY-AADC01, VY-FXN01 and VY-HTT01 AAV gene therapies for CNS disorders ex-USLink
Central Nervous System, Other/Miscellaneous
Genetic Disorders, Parkinson's Disease, Other Central Nervous System
OligonucleotidesGene TherapyExclusive
Africa, Asia, Europe, Middle East, NAFTA, South America
30.00 0.35 120.00 265.00 480.00 330.00 810.00 8.00 8.40 9.50 15.00 50.00
$50M for SMA; $60M for FA; $100M for HD; $60M for PD; $60M for Future | 8-15% on FA & Future; 5-12% on SMA & HD; 5-15% on PD | $120M for spinal muscular atrophy | $65M for FA; $45M for PD; $60M for HD (& $30M if co-dev); $65M for Future | 50/50 US profit split in HD if Genzyme elects to share US dev costs equally
79
1/2015AgenusBiotechIncyteLead Molecule 25.00 495.00 15.00
Co-Development, Co-Promotion, Equity, License, Option, Research
FOIAYesRetrocyte Display platform to develop immuno-oncology antibodies targeting GITR, OX40, LAG-3 & TIM-3LinkCancerBroad Focus CancerMonoclonals
Human Abs, Humanized Abs
ExclusiveWorldwide 35.00 60.00 0.28 220.00 85.00 425.00 70.00 495.00 15.00 15.00 15.00 15.00
Add'l 10M shares purchased 2/17 @ $6/sh, per Agenus' 9Q17 | 6-12% for Royalty-Bearing Products (TIM-3 & LAG-3); 15% royalty on GITR & OX-40 per 2/17 Amendment per Agenus' 9Q17 | 50/50 sharing of profits for the GITR and OX40 antibody programs, plus two of the add'l targets added in 11/15, per Agenus' 2016 10-K; PS eliminated per 2/17 Amendment per Agenus' 2016 10-K | $70M for Royalty-Bearing Products | Initially $20M for Profit-Share Products (GITR & OX-40); As of 2/17 Am, add'l milestones for GITR and OX-40 of $220M in aggregate, per Agenus' 9Q17 | $80M for each Royalty-Bearing Product | $490M (counting 2/17 add'l equity, and 1 Royalty-Bearing Product)
80
1/2015Johns HopkinsResearch InstitutionNovus TherapeuticsDiagnostic 0.19 0.89 5.00 License, TerminationFOIAYesCompanion diagnostic for use with galeterone to determine AR-V7 status of prostate cancer patientsLinkCancerProstateDiagnosticsExclusiveWorldwide 0.20 0.39 0.50 0.89 5.00 5.00 5.00 5.00
81
1/2015Nerviano Medical SciencesBiotechTiziana Life SciencesPhase II 3.50 41.70 3.50 Equity, License, SupplySEC FullYesMilciclib CDK inhibitor for cancerLinkCancerBreast, Liver, Lung, Other CancerSyntheticsSmall MoleculeExclusiveWorldwide 3.20 21.10 13.90 41.70 41.70 3.50 3.50 3.50 3.50 10.00
Nerviano will receive 4,233,616 new ordinary shares valued at 50.5p/share based on closing price on 1/16/15, £2.14 million total value (US$3.2M) | $21.1M for breast cancer
82
1/2015Sun Pharmaceutical, InSite VisionBiotechNicoxPhase III 3.00 17.25 10.00 LicenseFOIAYesAzaSite, AzaSite Xtra and BromSite in Europe, Middle East and AfricaLinkOphthalmicConjunctivitisDrug Delivery, Synthetics
Small Molecule, Sustained Release
Exclusive
Africa, Europe, Middle East
6.25 9.25 8.00 17.25 8.60 9.40 9.70 10.00 5-10% in Key Europe; 5-7% elsewhere
83
12/2014DurectBiotechSanten PharmaceuticalPreclinical 2.00 78.00 12.00 Development, License, SupplyFOIAYesSustained release SABER formulation of sirolimus immunosupressant for uveitisLinkOphthalmicUveitisDrug DeliverySustained ReleaseExclusiveWorldwide 21.00 23.00 55.00 78.00 6.75 9.30 10.65 12.00
84
12/2014
Eloxx Pharmaceuticals, Sevion Therapeutics
BiotechJohnson & Johnson, JanssenDiscovery 0.25 65.00 1.50 Development, License, Option, ResearchFOIAYesSpatially addressed library antibodies for SSTR3, Adiponectin 1 & 2 targetsLinkEndocrinological & MetabolicDiabetes, ObesityMonoclonalsExclusiveWorldwide 1.73 0.25 21.00 42.00 65.00 65.00 1.50 1.50 1.50 1.50
$1.725M over 2 yrs | $1M on option exercise, plus $20M in dev/reg milestones per Target | 2nd & 3rd Targets
85
12/2014Gilead, Kite PharmaBiotechAmgenDiscovery 60.00 850.00 15.00 Co-Development, License, OptionFOIAYesCAR-T & TCR immunotherapies to FLT3, DLL3 either PSMA or STEAP1 for cancerLinkCancerBroad Focus CancerCell Therapy - Stem Cells/FactorsExclusiveWorldwide 30.00 100.00 235.00 425.00 425.00 850.00 11.00 11.00 11.50 15.00
Amgen reimburses the first $10M for each Amgen Target thru IND | $165/hour | 11-14% in US & 8-11% ROW, plus add'l 1% for each Kite Target converted to an Option Product | $100M on 1st Marketing Approval | $35M on exercise of option to each Kite Target, plus $100M in add'l dev milestones for each Option Product, plus $100M on approval for each add'l Option Product
86
12/2014
Ludwig Cancer Research, Memorial Sloan Kettering
Research InstitutionAgenus, 4-AntibodyLead Molecule 1.00 101.88 6.00 LicenseFOIAYesHuman antibodies against glucocorticoid-induced TNFR-related protein (GITR), CD134 (OX-40) & TIM-3LinkCancerBroad Focus CancerMonoclonalsHuman AbsExclusiveWorldwide 52.50 18.38 71.88 30.00 101.88 5.00 5.00 5.00 6.00
$30M for GITR | 5-6% for TITR; 3% for Other Licensed Products | $52.5M for GITR | $14.375M for add'l GITR indications; plus $4M for Other Licensed Products
87
12/2014MacroGenicsBiotechJohnson & Johnson, JanssenPreclinical 50.00 700.00 30.00
Co-Development, Co-Promotion, Equity, License, Option, Termination
FOIAYesDuvortuxizumab (MGD011 humanized CD19 /CD3) for multiple B-cell malignanciesLinkCancerLeukemia, LymphomaMonoclonalsBispecificExclusiveWorldwide 75.00 0.28 210.00 215.00 550.00 150.00 700.00 10.00 10.00 10.00 13.00 30.00
$210M for DLBCL (diffuse large B-cell lymphoma) | $215M for add'l indications | 30% PS in NA if MacroGenics pays 20% of Global Dev Costs
88
12/2014Novimmune SABiotechTiziana Life SciencesPhase II 2.00 2.00 3.50 LicenseSEC FullYesForalumab (NI-0401 fully human anti-CD3 mAb) for inflammatory diseasesLinkAutoimmune/InflammatoryBroad Focus Autoimmune/InflammatoryMonoclonalsHuman AbsExclusiveWorldwide 2.00 2.00 3.50 3.50 3.50 3.50
89
12/2014Nuo TherapeuticsBiotechRohto PharmaceuticalDevice 3.00 4.00 9.00 Distribution, License, TerminationSEC FullYesAurix platelet and plasma therapy system for wound care in JapanLinkDermatologicWound HealingCell Therapy - Stem Cells/FactorsExclusiveAsia 1.00 4.00 4.00 9.00 9.00 9.00 9.00 10.00
90
12/2014Pfizer, Array BioPharmaBiotech
Seattle Genetics, Cascadian Therapeutics
Phase I 21.20 21.20 12.00 LicenseFOIAYesTucatinib (ONT-380 HER2 inhibitor) for cancerLinkCancerBreastSyntheticsSmall MoleculeExclusiveWorldwide 0.30 21.20 21.20 10.00 10.00 10.50 12.00
91
12/2014Zosano PharmaBiotechLillyPhase II 440.00 12.00
Co-Development, Equity, License, Supply, Termination
FOIAYesZP-PTH parathyroid hormone 1-34 transdermal micropatch for osteoporosisLinkBone DiseaseOsteoporosisDrug Delivery, Recombinant DNATransdermalExclusiveWorldwide 15.00 0.30 300.00 315.00 125.00 440.00 12.00 12.00 12.00 12.00 $15M equity at IPO
92
11/2014Arbutus BiopharmaBiotechDicerna PharmaceuticalsPreclinical 2.50 24.80 6.00 License, Supply, TerminationFOIAYesLipid nanoparticle technology to deliver DCR-PH1 for primary hyperoxaluria type 1LinkLiver & Gallbladder DiseasesOther Liver & Gallbladder DiseasesDrug Delivery, OligonucleotidesOther, RNAiSemi-exclusiveWorldwide 0.30 22.00 24.80 24.80 4.50 4.80 5.40 6.00 $306K for SOW #1-3 (see Supply agmt)
93
11/2014AVEO PharmaceuticalsBiotechIVERIC bioPreclinical 0.50 105.50 16.00 License, Option, TerminationFOIAYesTivozanib (VEGF inhibitor) for non-oncologic ocular diseases worldwide ex-AsiaLinkOphthalmic
Broad Focus Ophthalmic, Age-Related Macular Degeneration
SyntheticsSmall MoleculeExclusive
Africa, Europe, Middle East, NAFTA, South America
60.00 60.50 45.00 105.50 10.00 10.00 11.00 16.00
94
11/2014Children's Hospital of PhiladelphiaResearch InstitutionCerecor, Aevi Genomic MedicineDiscovery 1.00 24.25 4.00 License, Loan, ResearchFOIAYesBiobank disease samples to identify targets for pediatric rare and orphan genetic diseasesLinkOther/MiscellaneousGenetic DisordersOligonucleotidesGene TherapyExclusiveWorldwide 22.00 1.25 24.25 24.25 2.25 3.10 3.55 4.00
$500K upfront plus $100K AMF plus $120K patent reimb | TBD | $17.2M in sponsored R&D thru 11/16 research am, plus $4.75M per 2/17 am
95
11/2014Proteostasis TherapeuticsBiotechAstellas PharmaDiscovery 408.80 12.50
Co-Development, Co-Promotion, Equity, License, Loan, Option, Research
FOIAYesProtein folding platform to treat alpha-1 anti-trypsin deficiency via UPR modulationLinkOther/MiscellaneousGenetic DisordersScreening, SyntheticsSmall MoleculeExclusiveWorldwide 5.00 5.80 0.33 56.00 66.80 342.00 408.80 5.50 6.00 6.75 12.50
$5M equity via conversion of 7/14 note | 17.75 FTEs @ $325K/FTE | 5.5-7.5% if no co-dev; 6-12.5% if co-dev, depending on how far into clinical trials
96
10/2014EvonikBiotech
BioDelivery Sciences International
Lead Molecule 0.43 6.66 4.00 Development, License, Option, SupplyFOIAYesInjectable Depot Formulation of Buprenorphine for Opioid Dependence and PainLinkCentral Nervous SystemPainDrug DeliverySustained ReleaseExclusiveWorldwide 1.73 2.50 2.00 6.66 6.66 3.00 3.00 3.00 4.00 3% if Evonik manufactures, otherwise 4%
97
10/2014NewLink GeneticsBiotechRoche, GenentechPhase I 150.00 1,139.70 22.00
Co-Development, Co-Promotion, License, Option, Research, Termination
FOIAYesGDC-0919 (NLG919 IDO inhibitor) for cancer plus discovery of next generation IDO/TDO compoundsLinkCancerSolid TumorsSyntheticsSmall MoleculeExclusiveWorldwide 4.20 0.18 275.00 410.50 839.70 300.00 1,139.70 12.00 12.00 12.00 22.00
12 FTEs/yr for 2 yrs @ $175K/FTE | 16% royalty plus add'l 6% for US co-promotion | $150M for add'l indications; $260.5M for Next Generation Compound
98
10/2014Sorrento TherapeuticsBiotech
Lee’s Pharmaceutical, China Oncology Focus Limited
Phase II 1.00 50.10 10.00 Equity, LicenseFOIAYesSTI-­A1014 (anti­-PD-­L1 human MAb) in ChinaLinkCancerBroad Focus CancerMonoclonalsHuman AbsExclusiveAsia 3.60 3.00 0.50 8.10 42.00 50.10 8.20 9.28 9.64 10.00
99
9/2014CTI BioPharmaBiotechServierApproved 17.80 117.80 25.00
Co-Development, License, Supply, Termination
FOIAYesPixuvri (pixantrone) for B-cell non-Hodgkin lymphoma ex-US, Israel, Germany, UK, Austria & NordicLinkCancerLymphomaSyntheticsSmall MoleculeExclusive
Africa, Asia, Europe, Middle East, NAFTA, South America
0.27 49.00 66.80 51.00 117.80 18.75 22.50 23.75 25.00 15.00
14M Euros | 40M Euros | 50/50 split, up to 15M Euros each | 15-25% royalty in EU; 5% lower in ex-EU Territory | 39M Euros
100
9/2014Epirus BiopharmaceuticalsBiotechLivzon MabpharmPhase I 2.50 8.00 Co-Development, Equity, License, SupplyFOIAYesFive biosimilar products, including BOW015 (infliximab) in Greater ChinaLinkAutoimmune/InflammatoryRheumatoid ArthritisGenerics, MonoclonalsExclusiveAsia 2.50 2.50 2.50 6.70 7.48 7.74 8.00 20.00